Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United States
Henry Ford Cancer Institute, Detroit, Michigan Washington University Medical Campus, St Louis, Missouri Gabrail Cancer & Research Center, Canton, Ohio Virginia Cancer Specialists, Fairfax, Virginia Belgium
Grand Hopital de Charleroi (GHdC) - Hopital Notre Dame, Charleroi